IP Library Granted Patent US 7,345,153
Granted Patent B2
US 7,345,153 · App. 11/544,346 · Granted Mar 18, 2008

Compounds capable of inhibiting HIV-1 infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,345,153
App. No.
11/544,346
Granted
Mar 18, 2008
Kind
B2
Abstract

This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein + cell with an appropriate CD4 + cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.

Claims (7)

1. A monoclonal antibody or a portion of such monoclonal antibody effective to (a) specifically inhibit 67% or greater of fusion of a CD4+ PM-1 cell to a HeLa cell expressing envelope glycoprotein from HIV-1 JR-FL , and (b) inhibit 18% or less of fusion of a CD4+ SUP-T1 cell to a HeLa cell expressing envelope protein from HIV-1 LAI , wherein the antibody (i) does not crossreact with HIV-1 envelope glycoprotein or CD4, (ii) reacts with an antigen on the surface of a PM-1 cell having an approximate molecular weight of 44 kD, (iii) does not react with an antigen on the surface of a SUP-T1 cell, and (iv) is at least as active as monoclonal antibody PA-7 produced by the hybridoma designated PA-7 (ATCC Accession No. PTA-6638) in inhibiting fusion as recited in (a) above and less active than inonoclonal antibody PA-6 produced by the hybridoma designated PA-6 (ATCC Accession No. PTA-6637) in inhibiting fusion as recited in (b) above.

2. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is a chimeric monoclonal antibody.

3. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is a humanized monoclonal antibody.

4. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is a human monoclonal antibody.

5. The monoclonal antibody of claim 1 , wherein the portion of the monoclonal antibody is a single chain antibody or an antigen binding fragment.

6. The monoclonal antibody of claim 1 or the portion of such monoclonal antibody, wherein the monoclonal antibody or the portion of such monoclonal antibody is labeled with a detectable marker.

7. The monoclonal antibody of claim 6 or the portion of such monoclonal antibody, wherein the detectable marker is a radioactive isotope, an enzyme, a dye or biotin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2013
From: PROGENICS PHARMACEUTICALS, INC.
To: CYTODYN, INC.
Reel/Frame 029633/0837 →